Preeclampsia
Conditions
Brief summary
The purpose of this study is to figure out some of the differences in bodily function between women who have preeclampsia and those who do not. * This may eventually lead to an understanding of its cause. At this time, there is no known way to prevent preeclampsia, and the cause is not known. * The only treatment is delivery of the baby, even if it is premature, in order to decrease the risk to the mother.
Detailed description
* Preeclampsia is a pregnancy-related disorder that occurs in about 6% of all pregnancies. * In its mild for, preeclampsia involves high blood pressure. More severe forms of preeclampsia can lead to more serious pregnancy complications. * At this time, there is no known way to prevent preeclampsia, and the cause is not known. The only treatment is delivery of the baby, even if it is premature, in order to decrease the risk to the mother. * The purpose of this study is to figure out some of the differences in bodily function between women who have preeclampsia and those who do not. This may eventually lead to an understanding of its cause.
Interventions
PROCEDUREcollection of maternal blood specimen prior to delivery
approximately 5 cc. of maternal blood will be drawn prior to delivery
PROCEDUREcollection of placental cord blood after delivery
approximately 5 cc. of fetal cord blood from the umbilical cord blood vessel will be collected after cord is clamped
PROCEDUREcollection of placental tissue
within 10 minutes of delivery, the placenta will be radially transected, and a full-thickness slice from the central region removed using sterile technique by scalpel.This will be placed into a pre-prepared container of RNA preservation medium.
PROCEDUREcollection of strip of decidua from uterine lining from cesarean section deliveries
A strip of decidua will be removed from the upper lip of uterine incision by the surgeon and placed in RNA preservation medium.
Sponsors
University of Rochester
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Gravidas at 32-42 weeks gestation,who have preeclampsia as defined by Sibai et al, 1997. * Control patients: Gravidas without history of hypertension of any kind, and matched to cases for parity, gestational age, labor status, maternal age, and race.
Exclusion criteria
* Prior betamethasone administration, fetal growth restriction (\<3%ile), prior chronic hypertension (nonpregnant or \< 20 weeks gestation any pregnancy), chorioamnionitis, major fetal anomaly or chromosome abnormality, multiple gestation, and maternal diabetes (any class except diet-controlled gestational).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Relative pattern of expression in cases and matched controls of a robust set of genes in the VEGF/sFLT mediated model for preeclampsia in the placenta and decidua | 1- 2 years |
Secondary
| Measure | Time frame |
|---|---|
| From this expression pattern,determine the validity of 18s ribosomal subunit as an endogenous control in this tissue. | 1- 2 years |
| Using relative expression analysis in an embedded set of control subjects, determine whether common variables e.g. labor, parity independently influence expression of these genes of interest in the tissues studied | 1 - 2 years |
| Determine the population variance for each gene of interest | 1 - 2 years |
Countries
United States
Outcome results
None listed